【US Stock Market Movement】Vaxcyte surged on October 9: Accelerated cancer vaccine development + pneumonia vaccine
Bitget异动解读2026/10/09 15:45Vaxcyte’s Surge on October 9 Explained
Keywords: Cancer vaccine acceleration, pneumonia vaccine
1. On October 9, reports indicated that the U.S. National Institutes of Health plans to accelerate cancer vaccine research. The share prices of several vaccine developers rose, with Vaxcyte increasing by 6.98% that day; the company is primarily engaged in clinical-stage vaccine research and development, and related sector news served as an external catalyst.
2. On October 5, the company announced topline data from the VAX-31 adult phase III OPUS-1 trial, showing that all pre-set primary endpoints were met across all age groups. Among adults aged 50 and above, all 28 shared serotypes met the non-inferiority standard, while the 3 unique serotypes and cross-reactive serotype 20B met the superiority standard. VAX-31 is a 31-valent pneumococcal conjugate vaccine, and the company’s pipeline is targeting a market of approximately $8.5 billion.
(Disclaimer: This content is collated and generated by AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Chevron has suspended production operations at five facilities in the U.S. Gulf region.
Chevron (CVX.US) has evacuated personnel and shut down production operations at five facilities in the US Gulf region, while another four offshore platforms continue production.
Chevron deploys related technology to protect Gulf of Mexico coastal business facilities
Chevron (CVX.US): Deployed relevant technologies to protect Gulf Coast business facilities during Hurricane Isaias.
Crypto prices
More
